Zykadia

ceritinib · Novartis Europharm Limited
AUTHORISED IN THE EU

What Zykadia is used for

Zykadia is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) previously treated with crizotinib.

Approved use, as published by the European Medicines Agency.

Key facts

Brand
Zykadia
Active substance
ceritinib
Disease area
Carcinoma, Non-Small-Cell Lung
Medicine group
Antineoplastic agents
ATC code
L01XE
Marketing authorisation holder
Novartis Europharm Limited
Authorised in the EU since
2015

Official information

In the USA

Same active substance: Zykadia

In India

Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.

Common questions

What is Zykadia used for?

Zykadia is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) previously treated with crizotinib.

What is the active substance in Zykadia?

Zykadia contains ceritinib.

Who makes Zykadia?

The EU marketing authorisation holder is Novartis Europharm Limited.

Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.

← All specialty medicines, EU

For information only, not medical advice. This page is a plain-language summary written from standard prescribing information and the public guides linked below. Brands sometimes change their formula, so always check the composition printed on the pack. Doses here are typical adult doses; yours may differ. Do not start, stop or change a medicine without your doctor or pharmacist, and keep all medicines away from children. In an emergency, call 112 (India) or your local emergency number.